Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of JMKX000197 for malignant pleural effusion
CTR20262357Phase 2Active
- Sponsor
- Zhejiang Hangyu Pharmaceutical
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JMKX000197 in malignant pleural effusion (MPE), sponsored by Zhejiang Hangyu Pharmaceutical. Started Jun 2026; status: active.
02
Drugs
JMKX000197
03
Conditions
malignant pleural effusion (MPE)
Beyond the preview
Go deeper on CTR20262357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262357.